Your browser doesn't support javascript.
loading
Direct-to-consumer testing as consumer initiated testing: compromises to the testing process and opportunities for quality improvement.
Shih, Patti; Sandberg, Sverre; Balla, Jan; Basok, Banu Isbilen; Brady, Jennifer J; Croal, Bernard; De Vos, Nathalie; Karlsson, Mathias; Kedars, Piret; Ozben, Tomris; Pijanovic, Marina; Plebani, Mario; Orth, Matthias.
  • Shih P; Australian Centre for Health Engagement Evidence and Values, School of Health & Society, 8691 University of Wollongong , Wollongong, Australia.
  • Sandberg S; Noklus, Bergen, Norway.
  • Balla J; Department of Public Global Health and Primary Care, University of Bergen, Bergen, Norway.
  • Basok BI; Noklus, The Norwegian Organization for Quality Improvement of Laboratory Examinations, Haraldsplass Diakonale Sykehus AS, Bergen, Norway.
  • Brady JJ; Department of Public Global Health and Primary Care, University of Bergen, Bergen, Hordaland, Norway.
  • Croal B; Klinicka biochemia a imunochemia, Analyticko-diagnosticke laboratorium, Kovacska, Presov, Slovakia.
  • De Vos N; Faculty of Medicine, University of Health Sciences Izmir, Izmir, Türkiye.
  • Karlsson M; Department of Clinical Biochemistry, Children's Health Ireland at Temple St, Dublin 1, Ireland.
  • Kedars P; School of Medicine, University College Dublin, Dublin, Ireland.
  • Ozben T; Aberdeen Royal Infirmary, NHS Grampian-Clinical Biochemistry, Aberdeen, Aberdeen, UK.
  • Pijanovic M; LHUB-ULB Clinical Chemistry, Université Libre de Bruxelles, Bruxelles, Belgium.
  • Plebani M; Department of Medical Sciences, Section of Clinical Chemistry, Uppsala University, Uppsala, Sweden.
  • Orth M; Central Laboratory, East Tallinn Central Hospital, Tallinn, Harjumaa, Estonia.
Clin Chem Lab Med ; 2024 Aug 14.
Article en En | MEDLINE | ID: mdl-39141796
ABSTRACT
Direct-to-consumer testing (DTCT) refers to commercial laboratory tests initiated by laypersons without the involvement of healthcare professionals. As this market grows in size and variety of products, a clear definition of DTCT to ground the conceptualization of their harms and benefits is needed. We describe how three different modalities of DTCT (home self-testing, self-sampled tests, and direct access tests) present caveats to the traditional testing process ('brain-to-brain loop'), and how this might differ between medical vs. non-medical laboratories. We make recommendations for ways to improve quality and reduce errors with respect to DTCT. The potential benefits and harms of DTCT will invariably depend on the context and situation of individual consumers and the types of tests involved. Importantly, implications for both consumers and the healthcare system should be considered, such as the effects on improving health outcomes and reducing unnecessary testing and use of clinical resources. 'Consumer initiation' must be a central defining characteristic of DTCT, to clearly demarcate the key drawbacks as well as opportunities of this type of testing from a laboratory specialists' perspective. The concept of 'consumer initiated testing' should also help define DTCT regulation, and provide a locus of efforts to support consumers as the main decision-makers in the purchasing and conducting of these tests in the absence of clinician gatekeeping.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article